2Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis,2002,34:730-751.
3Un'ea M, Rives S, Cruz O, et al. Nosoconfial infections among pediatric hematology/ontology patients: results of a prospective incidence study. Am J Infect Control,2004,32:205-208.
4Latiff Z, Zulkifli SZ, Jamal R. Risk assessment and microbiological profile of infections in paediatric cancer patients with febrile neutropenia. Malays J Pathol,2002 ,24 :83-89.
5Pierre YB, Thierry C. Baeteremia Due to viridans streptococci in neutropenic patients : a review. Am J Med, 1994,97:256-264.
6Elting LS, Rubenstein EB, Rolston KV. Outcomes of bacteremia in patients with cancer and neutropenia : observations from two decades of epidemiological and clinical trials. Clin Infect Dis, 1997, 25:247-259.
7Link H, Bohme A, Comely OA,et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol, 2003, 82 Suppl 2 : S105-117.
8Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis, 2004, 39 Suppl 1 :S49-52.
9Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother, 2006, 57: 176-189.
10Glasmacher A, von Lilienfeld-Toal M, Schulte S,et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect, 2005,11 Suppl 5:17-23.
